With the stock market losing ground on the back of expectations of a possible interest rate hike by the Fed next month, fueled by strong non-farm payroll and unemployment data...
Keep Reading →
November 9 - Market Movers, News
In order to diversify portfolios and reduce exposure to one particular country, it is generally a good idea for retail investors to buy shares of companies which generate a major...
Keep Reading →
September 30 - Hedge Funds, News
At Insider Monkey, we track more than 700 elite hedge funds and use their combined wisdom to identify 15 exceptional small-cap stocks every quarter, which our backtesting and ...
Keep Reading →
September 20 - Hedge Funds, News
The S&P 500 Health Care Index has advanced by 21.11% over the past three-year period, which is significantly higher than the S&P 500’s return of 10.30% over the same time span...
Keep Reading →
September 19 - Hedge Funds, News
David Tepper of Appaloosa Management, who has the distinction of having Carnegie Mellon's business school being named after him, is without a doubt an accomplished and respected...
Keep Reading →
September 13 - Hedge Fund Analysis, Hedge Funds, News
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) shares reached as high as $83 per share in pre-market trading Monday, or over 18% higher than the stock’s closing price ...
Keep Reading →
July 27 - Hedge Funds, News
This article is temporarily removed from Insider Monkey.
Keep Reading →
July 23 - Hedge Funds, News
Conan Laughlin’s North Tide Capital posted impressive first quarter returns of 10.1% from its 14 long positions in companies valued at $1 billion or greater.
Keep Reading →
April 17 - Hedge Funds, News
Charter Oak Partners Management is a fundamentally driven Long/Short hedge fund that focuses mainly on equity investments. It was founded by Jerrold N.
Keep Reading →
March 26 - Hedge Funds, News
Chemical nerve agents have garnered much media coverage recently, but receiving less attention are the companies involved in the development of countermeasures to these and biological...
Keep Reading →
September 23 - News
Since 1983, Depakote ER has been a good source of revenue for drug manufacturers. The drug is mainly used in the treatment of bipolar disorder, migraines, and seizures.
Keep Reading →
September 13 - News
I follow quite a lot of companies, so the usefulness of a watchlist to me cannot be overstated.
Keep Reading →
September 12 - News
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis...
Keep Reading →
September 10 - News
Orphan drug status, which is given to drugs meant for the treatment of rare diseases, offers drug developers a path to faster approval and enhanced market exclusivity.
Keep Reading →
September 6 - News
In the 21st century investor’s toolkit, there are dozens of methods shareholders can use to monitor their holdings.
Keep Reading →
August 27 - News
To many investors, hedge funds are assumed to be overrated, old financial vehicles of an era lost to time.
Keep Reading →
August 25 - News
Even with the broad-based S&P 500 retracing for three straight days amid worries that the Federal Reserve may begin paring back its monthly bond-buying program as early as next...
Keep Reading →
August 9 - News
It's finally Friday, and the S&P 500 is trying its hardest to find a reason to be happy.
Keep Reading →
August 3 - News
The company broke open a bombshell on Monday when it announced that it would break its business into three new divisions -- two focused around drugs, vaccines, and consumer products...
Keep Reading →
July 31 - News
The United States Court of Appeals is making this one miserable summer for Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA).
Keep Reading →
July 29 - News
Biotechnology medicine manipulates the genetic material of living organisms to produce pharmaceuticals, which in many instances are designed to combat diseases once considered...
Keep Reading →
July 25 - News
Last week's new corporate bond issues totaling nearly $17 billion marked four consecutive weeks below $20 billion.
Keep Reading →
June 27 - News
A new Supreme Court ruling presents pharmaceutical companies with a tough choice -- stop paying generic-drug producers to withhold generic options from the market, or risk getting...
Keep Reading →
June 20 - News
Nothing interests a value investor more than bad news. Where there's a lack of enthusiasm, there's usually a cheap stock. Hospira, Inc.
Keep Reading →
June 14 - News
Searching for potential stock investments can be a daunting task.
Keep Reading →
June 13 - Hedge Funds
Generic producers are often regarded as the safer players within BioPharma.
Keep Reading →
June 13 - News
Does the house of health care have a glass ceiling? For women looking to advance in the health care industry, that might appear to be the case. Consider that the U.S.
Keep Reading →
June 13 - News
Generic-drug makers have considerable tailwinds, making their outperformance in the past year unsurprising.
Keep Reading →
June 6 - News
Virtually every investor is quite familiar with the names of big pharmaceutical giants such as GlaxoSmithKline plc (ADR) (NYSE:GSK), Eli Lilly & Co.
Keep Reading →
May 30 - News
Recently, Actavis Inc (NYSE:ACT) announced that it would acquire Warner Chilcott Plc (NASDAQ:WCRX) for around $8.5 billion in total consideration.
Keep Reading →
May 30 - News
Mylan Inc. (NASDAQ:MYL) was in 27 hedge funds' portfolio at the end of March. MYL shareholders have witnessed a decrease in enthusiasm from smart money of late.
Keep Reading →
May 28 - News
Editor's Note: Related Tickers: Goldman Sachs Group, Inc. (NYSE:GS), Citigroup Inc. (NYSE:C), J.C. Penney Company, Inc. (NYSE:JCP), Herbalife Ltd.
Keep Reading →
May 17 - Hedge Funds
Actavis Inc (NYSE:ACT), the largest generic drug company in the US, just got even bigger.
Keep Reading →
May 1 - News
Last week we focused on five can't-miss earnings reports.
Keep Reading →
April 29 - News
Within the next few days, stocks for two orphan drugmakers could either soar or sink. Both Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) and Raptor Pharmaceutical Corp.
Keep Reading →
April 24 - News
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), a pharmaceuticals company that makes money off of branded drugs as well as generics, is an interesting example of a company...
Keep Reading →
April 23 - News
Big pharma loves Obamacare, right? After all, the main lobbying group for big pharma, the Pharmaceutical Researchers and Manufacturers of America, or PhRMA, spent $150 million...
Keep Reading →
March 23 - News
At the moment, there are a multitude of methods investors can use to monitor publicly traded companies.
Keep Reading →
March 20 - Hedge Funds
U.S. generics firm Actavis Inc (NYSE:ACT), previously Watson Pharmaceuticals, reported a strong jump in its revenues in the fourth quarter and total earnings for 2012.
Keep Reading →
March 17 - News
Occasionally some of my friends ask me why I am hedged and market neutral in my investing. My answer is always the same.
Keep Reading →
February 22 - News
Here at The Motley Fool, we believe the best way to invest and maximize returns is by buying strong companies and owning them for a long time.
Keep Reading →
February 11 - News
Its narcolepsy drug Provigil saw generic competition from Par Pharmaceutical Companies, Inc. (NYSE:PRX) and Mylan Inc.
Keep Reading →
February 9 - News